Eli Lilly's Mounjaro (tirzepatide) has rapidly seized the top position in India's pharmaceutical market, becoming the highest-selling medicine by value just eight months after its March 2025 launch. Driven by India's urgent need for diabetes and obesity treatments, Mounjaro clocked an unprecedented ₹100 crore in October sales alone, contributing to a total revenue of ₹333 crore by the end of October (Pharmarack data). Its volume usage is reportedly ten times higher than competitor Novo Nordisk's Wegovy.

As a new class of metabolic drug, Mounjaro was initially approved for Type-II diabetes but is widely used off-label for significant weight reduction. This success highlights the vast potential and challenges within India's estimated ₹752 crore anti-obesity market. While demand is surging, the high monthly cost (₹14,000–₹17,500) makes it inaccessible to many of the 100 million Indians suffering from diabetes and obesity, underscoring a pivotal moment in the nation's healthcare trajectory.